Panobinostat (LBH589) in Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 13, 2017

Conditions
MelanomaMalignant Melanoma
Interventions
DRUG

LBH589

Taken orally three times per week.

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Novartis

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER